Search

Displaying results 2691 - 2700 of 10000 in total
  1. Drug

    Hydroxyethyl cellulose

    go.drugbank.com/drugs/DB11602
    Approved

    It is often used as an ingredient in ophthalmic pharmaceutical preparations such as artificial tear solutions and adjunct agent in topical drug formulations to facilitate the delivery of drugs with hydrophobic … It is used as a key ingredient in many household cleaning products, lubricants and cosmetics due to its non-ionic and water-soluble nature.

  2. Drug

    Meningococcal polysaccharide vaccine group Y

    go.drugbank.com/drugs/DB13888
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup Y.

    Mixtures: NIMENRIX 0,5 ML IM ENJEKSIYON ICIN TOZ ICEREN FLAKON VE COZUCU ICEREN KULLANIMA HAZIR ENJEKTOR, 1 ADET
  3. Drug

    Asciminib

    go.drugbank.com/drugs/DB12597
    ApprovedInvestigational

    Existing inhibitors of ABL compete at the ATP binding sites of these proteins and can be classified into those that target the active conformation of the kinase domain ([dasatinib], [bosutinib]) and those … More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995] which serves as a driver of CML proliferation in most patients with the disease.

  4. Drug

    Decitabine

    go.drugbank.com/drugs/DB01262
    ApprovedInvestigational

    Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. … [A2263, A2264, A2265, A215317, L14962] Decitabine was developed by MGI Pharma/SuperGen Inc. and was approved by the FDA for the treatment of MDS on February 5, 2006.

  5. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    By promoting the expression of AADC, eladocagene exuparvovec leads to the development of motor function in patients with AADC deficiency. … [A253697,L43672] Before the approval of this gene therapy, the treatment options for patients with AADC deficiency were limited to attempts to increase monoamine neurotransmitter production, decrease neurotransmitter

  6. Drug

    Favipiravir

    go.drugbank.com/drugs/DB12466
    ApprovedInvestigational

    [A191688,A191772,A191775] Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for … [A191688,A191721] The antiviral targets RNA-dependent RNA polymerase (RdRp) enzymes, which are necessary for the transcription and replication of viral genomes.

  7. Drug

    Oxaliplatin

    go.drugbank.com/drugs/DB00526
    ApprovedInvestigational

    [A797] However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. … [A260396] However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic

  8. Drug

    Quazepam

    go.drugbank.com/drugs/DB01589
    ApprovedIllicit

    It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. … [L44913] It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors and low affinity for other

  9. Drug

    Albumin Aggregated

    go.drugbank.com/drugs/DB14230
    Approved

    Albumin aggregated is an ingredient in the DRAXIMAGE MAA kit for the preparation of technetium tc99m albumin aggregated injection. … [L12816] This imaging agent is used to assess lung perfusion and for the evaluation of peritoneovenous (LeVeen) shunt patency.

  10. Drug

    Elranatamab

    go.drugbank.com/drugs/DB15395
    ApprovedInvestigational

    [L47815] On August 14, 2023, the FDA granted accelerated approval to elranatamab for the treatment of multiple myeloma. … Elranatamab is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager.

    Categories: Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engagerSynonyms: IMMUNOGLOBULIN G2-KAPPA, ANTI-(HOMO SAPIENS T-CELL SURFACE GLYCOPROTEIN CD3 EPSILON CHAIN CD3E (T-CELL SURFACE ANTIGEN T3/LEU-4 EPSILON CHAIN)), HUMAN-MUS MUSCULUS MONOCLONAL DISULFIDE WITH IMMUNOGLOBULIN